# Equillium, Inc.: overview EQ · Nasdaq · CIK 1746466 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/eq.md) · [Financials](/companies/eq/financials.md) · [Filings](/companies/eq/filings.md) · [Insiders](/companies/eq/insiders.md) Latest reported revenue: [$4.4m](/filings/0001193125-26-124143.md) for Q4 FY2024, three months to 2024-12-31, from the 10-K filed Mar 25, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-124143). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [12.2](/filings/0001193125-25-280202.md) | [4.4 d](/filings/0001193125-26-124143.md) | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(5.6%)](/filings/0001193125-25-280202.md) | [(107.0%) d](/filings/0001193125-26-124143.md) | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | [(0.1%)](/filings/0001193125-25-280202.md) | [(131.9%) d](/filings/0001193125-26-124143.md) | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [0.00](/filings/0001193125-25-280202.md) | not reported | [(0.24)](/filings/0001193125-26-221625.md) | [(0.16)](/filings/0001193125-26-349235.md) | [(0.06)](/filings/0001193125-25-280202.md) | not reported | [(0.06)](/filings/0001193125-26-221625.md) | [(0.04)](/filings/0001193125-26-349235.md) | | Free cash flow | $m | [(7.7) d](/filings/0001193125-25-280202.md) | [(3.3) d](/filings/0001193125-26-124143.md) | [(8.2)](/filings/0001193125-26-221625.md) | [(3.0) d](/filings/0001193125-26-349235.md) | [(8.4) d](/filings/0001193125-25-280202.md) | [(3.2) d](/filings/0001193125-26-124143.md) | [(4.3)](/filings/0001193125-26-221625.md) | [(4.2) d](/filings/0001193125-26-349235.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | [15.8](/filings/0000950170-24-035919.md) | [36.1](/filings/0000950170-25-045726.md) | [41.1](/filings/0001193125-26-124143.md) | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | [(393.9%)](/filings/0000950170-24-035919.md) | [(40.2%)](/filings/0000950170-25-045726.md) | [(20.1%)](/filings/0001193125-26-124143.md) | not reported | | Net margin | % | not reported | [(396.1%)](/filings/0000950170-24-035919.md) | [(37.0%)](/filings/0000950170-25-045726.md) | [(19.6%)](/filings/0001193125-26-124143.md) | not reported | | Diluted EPS | $ per share | [(1.36)](/filings/0000950170-23-009492.md) | [(1.85)](/filings/0000950170-24-035919.md) | [(0.38)](/filings/0000950170-25-045726.md) | [(0.23)](/filings/0001193125-26-124143.md) | [(0.39)](/filings/0001193125-26-124143.md) | | Free cash flow | $m | [(32.1)](/filings/0000950170-23-009492.md) | [(9.0)](/filings/0000950170-24-035919.md) | [(21.8)](/filings/0000950170-25-045726.md) | [(19.1)](/filings/0001193125-26-124143.md) | [(22.8)](/filings/0001193125-26-124143.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/eq/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $20.7m | 6,494,571 | | Not compared | | [Decheng Capital LLC](/funds/2010850.md) | 2026-06-30 | $14.2m | 4,447,308 | | Unchanged | | [Affinity Asset Advisors, LLC](/funds/1773195.md) | 2026-06-30 | $13.1m | 4,100,000 | | Added +2,873,690 | | [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $13.0m | 6,494,571 | | Not compared | | [ADAR1 Capital Management, LLC](/funds/1940272.md) | 2026-06-30 | $12.0m | 3,758,569 | | Added +31,910 | | [Aberdeen Group plc](/funds/1716774.md) | 2026-06-30 | $11.6m | 3,631,659 | | Added +278,822 | | [Woodline Partners LP](/funds/1784547.md) | 2026-06-30 | $11.2m | 3,500,901 | | Unchanged | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $9.9m | 3,096,336 | | Unchanged | | [STEMPOINT CAPITAL LP](/funds/1952142.md) | 2026-06-30 | $6.5m | 2,016,607 | | New +2,016,607 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $5.8m | 1,822,812 | | Added +38,340 | ## Recent filings [All 462 filings](/companies/eq/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-05 | 17:06 ET | [8-K](/filings/0001193125-26-414364.md) | 8.01 Other events | 0001193125-26-414364 | | 2026-08-13 | 16:15 ET | [10-Q](/filings/0001193125-26-349235.md) | Quarterly report, period 2026-06-30 | 0001193125-26-349235 | | 2026-08-13 | 16:10 ET | [8-K](/filings/0001193125-26-349182.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-349182 | | 2026-05-29 | 16:05 ET | [8-K](/filings/0001193125-26-248246.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-248246 | | 2026-05-13 | 16:10 ET | [10-Q](/filings/0001193125-26-221625.md) | Quarterly report, period 2026-03-31 | 0001193125-26-221625 | | 2026-05-13 | 16:05 ET | [8-K](/filings/0001193125-26-221595.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-221595 | | 2026-04-15 | 09:00 ET | [DEF 14A](/filings/0001193125-26-156092.md) | Proxy statement, period 2026-05-28 | 0001193125-26-156092 | | 2026-03-25 | 16:15 ET | [10-K](/filings/0001193125-26-124143.md) | Annual report, period 2025-12-31 | 0001193125-26-124143 | | 2026-03-25 | 16:10 ET | [8-K](/filings/0001193125-26-124107.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-124107 | | 2026-03-13 | 08:15 ET | [8-K](/filings/0001193125-26-105083.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-26-105083 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-124143.md), filed Mar 25, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1746466 - Tickers: EQ - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 17:10 ET. No prices; not investment advice.